Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

3 Jun 2022

Abstract excerpt

Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline BRCA1/2 mutated and homologous recombination repair deficient (HRD) tumors are likely also PARP-inhibitor sensitive. Clinical validity and utility of various HRD biomarkers are under investigation. The REpair CAPacity (RECAP) test is a functional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35662281
DOI: 10.1038/s41388-022-02363-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness testsPMID 35662281Read ↗

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian CarcinomasSemantic proximity Read ↗

Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene DefectsSemantic proximity Read ↗

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissueSemantic proximity Read ↗

Whole Genome Analysis Identifies Homologous Recombination Deficiency in Cancers with BRCA1/2 Wild-Type and BRCA1/2 Structural VariantsSemantic proximity Read ↗

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read ↗

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision OncologySemantic proximity Read ↗

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer CohortSemantic proximity Read ↗

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.Semantic proximity Read ↗

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-ProficientSemantic proximity Read ↗

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.Semantic proximity Read ↗

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.